1. Generics Bulletin
  2. >>Business
  3. >>Deals

Sandoz Agrees $265m Settlement To Resolve US Pricing Litigation

Firm Says Purchasers Deal Underscores ‘Commitment To Integrity And Sound Governance’

 
• By Dave Wallace

Sandoz has agreed a $265m settlement in the US to resolve generic pricing antitrust class action litigation with direct purchaser plaintiffs, as part of a deal that contains no admission of wrongdoing on the part of the generics giant.

265 number on orange background
Sandoz will pay out $265m to resolve antitrust class action litigation • Source: Shutterstock

Sandoz US and its Fougera Pharmaceuticals subsidiary will pay a total of $265m to direct purchaser plaintiffs in US antitrust litigation over generic pricing, as part of a deal that the generics giant has reached to resolve the matter in exchange for “full release of all claims by the class.”

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Hikma Secures US Rights To Novugen’s Generic Trametinib

 
• By Adam Zamecnik

The move adds another compound with the coveted 180-day exclusivity to Hikma’s portfolio for an undisclosed sum.

Xbrane Approves Deal Giving Away Cimzia Rival To Alvotech

 
• By Adam Zamecnik

After announcing the agreement last month, Xbrane has now approved its deal with Alvotech as part of an extra general meeting.

Polpharma Looks To Supercharge Biosimilar Development With Help Of Chime

 
• By Dean Rudge

With six biosimilars reportedly in development, Polpharma Biologics has linked up with Chinese CDMO Chime Biologics, looking to tap its “all-in-one solutions to accelerate biosimilar development and reduce the time-to-market” for an undisclosed biosimilar product.

Fresenius Divests Brazilian Sites To EMS Amid Structural Streamlining

 
• By Adam Zamecnik

The divestment marks a further step in Fresenius’ ongoing strategy towards a more optimized and simplified company structure while doubling down on new endeavors in the Biopharma space.

More from Business